Fructose- 1,6-Bisphosphate Supports Cerebral Energy Metabolism in Pigs after Ischemic Brain Injury Caused by Experimental Particle Embolization
DOI:
https://doi.org/10.1532/HSF98.20061079Abstract
Background. Fructose-1,6-bisphosphate (FDP) is a high-energy intermediate that enhances glycolysis, preserves cellular adenosine triphosphate stores, and prevents the increase of intracellular calcium in ischemic tissue. Since it has been shown to provide metabolic support to the brain during ischemia, we planned this study to evaluate whether FDP is neuroprotective in the setting of combining hypothermic circulatory arrest (HCA) and irreversible embolic brain ischemic injury.
Methods. Twenty pigs were randomly assigned to receive 2 intravenous infusions of either FDP (500 mg/kg) or saline. The first infusion was given just before a 25-minute period of HCA and the second infusion immediately after HCA. Immediately before HCA, the descending aorta was clamped and 200 mg of albumin-coated polystyrene microspheres (250-750 mm in diameter) were injected into the isolated aortic arch in both study groups.
Results. There were no significant differences between the study groups in terms of neurological outcome. Brain lactate/pyruvate ratio was significantly lower (P = .015) and brain pyruvate levels (P = .013) were significantly higher in the FDP group compared with controls. Brain lactate levels were significantly higher 8 hours after HCA (P = .049).
Conclusion. The administration of FDP before and immediately after HCA combined with embolic brain ischemic injury was associated with significantly lower brain lactate/pyruvate ratio and significantly higher levels of brain pyruvate, as well as lower lactate levels 8 hours after HCA. FDP seems to protect the brain by supporting energy metabolism. The neurological outcome was not improved, most likely resulting from the irreversible nature of the microsphere occlusion.
References
Bickler PE, Buck LT. 1996. Effects of fructose-1,6-bisphosphate on glutamate release and ATP loss from rat brain slices during hypoxia. J Neurochem 67:1463-8.nBickler PE, Kelleher JA. 1992. Fructose-1,6-bisphosphate stabilizes brain intracellular calcium during hypoxia in rats. Stroke 23:1617-22.nCardenas A, Hurtado O, Leza JC, et al. 2000. Fructose-1,6-bisphosphate inhibits the expression of inducible nitric oxide synthase caused by oxygen-glucose deprivation through the inhibition of glutamate release in rat forebrain slices. Naunyn Schmiedebergs Arch Pharmacol 362:208-12.nDahlbacka S, Heikkinen J, Kaakinen T, et al. 2005. pH-stat versus alpha-stat acid-base management strategy during hypothermic circulatory arrest combined with embolic brain injury. Ann Thorac Surg 79:1316-25.nDuebener LF, Hagino I, Sakamoto T, et al. 2002. Effects of pH management during deep hypothermic bypass on cerebral microcirculation: alpha-stat versus pH-stat. Circulation 106:I103-8.nGobbel GT, Chan TY, Gregory GA, et al. 1994. Response of cerebral endothelial cells to hypoxia: modification by fructose-1,6-bisphosphate but not glutamate receptor antagonists. Brain Res 653:23-30.nHassinen IE, Nuutinen EM, Ito K, et al. 1991. Mechanism of the effect of exogenous fructose 1,6-bisphosphate on myocardial energy metabolism. Circulation 83:584-93.nHillered L, Persson L, Ponten U, et al. 1990. Neurometabolic monitoring of the ischaemic human brain using microdialysis. Acta Neurochir (Wien) 102:91-7.nJuvonen T, Weisz DJ, Wolfe D, et al. 1998. Can retrograde perfusion mitigate cerebral injury after particulate embolization? A study in a chronic porcine model. J Thorac Cardiovasc Surg 115:1142-59.nKaakinen T, Naukkarinen A, Tuominen H, et al. 2005. Neuronal ultra-structure is preserved by fructose-1,6-bisphosphate after hypothermic circulatory arrest in pigs. J Thorac Cardiovasc Surg 130:1475-6.nKawachi Y, Nakashima A, Toshima Y, et al. 2003. Stroke in thoracic aortic surgery: outcome and risk factors. Asian Cardiovasc Thorac Ann 11:52-7.nKelleher JA, Chan TY, Chan PH, et al. 1996. Protection of astrocytes by fructose 1,6-bisphosphate and citrate ameliorates neuronal injury under hypoxic conditions. Brain Res 726:167-73.nKuluz JW, Gregory GA, Han Y, et al. 1993. Fructose- 1,6-bisphosphate reduces infarct volume after reversible middle cerebral artery occlusion in rats. Stroke 24:1576-83.nLi LY, Wang HY, Shi JH. 1994. Protective effect of 1,6-diphosphate fructose in ischemic renal failure in elderly rats. Zhonghua Yi Xue Za Zhi 74:9-12,61.nMarkov AK, Causey AL, Didlake RH, et al. 2002. Prevention of alpha-naphthylthiourea-induced pulmonary edema with fructose-1,6-diphosphate. Exp Lung Res 28:285-99.nMcCullough JN, Zhang N, Reich DL, et al. 1999. Cerebral metabolic suppression during hypothermic circulatory arrest in humans. Ann Thorac Surg 67:1895-9.nPersson L, Hillered L. 1992. Chemical monitoring of neurosurgical intensive care patients using intracerebral microdialysis. J Neurosurg 76:72-80.nRomsi P, Kaakinen T, Kiviluoma K, et al. 2003. Fructose-1,6-bisphosphate for improved outcome after hypothermic circulatory arrest in pigs. J Thorac Cardiovasc Surg 125:686-98.nSawchuk A, Canal D, Slaughter M, et al. 1986. A comparison between fructose 1,6-diphosphate, glucose, or normal saline infusions and species-specific blood exchange transfusions in the treatment of bowel ischemia. Surgery 100:665-70.nSola A, Panes J, Xaus C, et al. 2003. Fructose-1,6-biphosphate and nucleoside pool modifications prevent neutrophil accumulation in the reperfused intestine. J Leukoc Biol 73:74-81.nTavazzi B, Cerroni L, Di Pierro D, et al. 1990. Oxygen radical injury and loss of high-energy compounds in anoxic and reperfused rat heart: prevention by exogenous fructose-1,6-bisphosphate. Free Radic Res Commun 10:167-76.nTavazzi B, Starnes JW, Lazzarino G, et al. 1992. Exogenous fructose-1,6-bisphosphate is a metabolizable substrate for the isolated normoxic rat heart. Basic Res Cardiol 87:280-9.nTrimarchi GR, Arcadi FA, Imperatore C, et al. 1997. Effects of fructose-1,6-biphosphate on microsphere-induced cerebral ischemia in the rat. Life Sci 61:611-22.n
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
